![Renu Gupta](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Renu Gupta
Directeur/Membre du Conseil chez Aim At Melanoma Foundation
Postes actifs de Renu Gupta
Sociétés | Poste | Début | Fin |
---|---|---|---|
Harvard Medical School | Corporate Officer/Principal | 20/01/2011 | - |
Aim At Melanoma Foundation | Directeur/Membre du Conseil | 20/01/2011 | - |
Historique de carrière de Renu Gupta
Anciens postes connus de Renu Gupta
Sociétés | Poste | Début | Fin |
---|---|---|---|
INSMED INCORPORATED | Directeur Technique/Scientifique/R&D | 09/12/2010 | 02/04/2014 |
Insmed Ltd.
![]() Insmed Ltd. Pharmaceuticals: MajorHealth Technology Insmed Ltd. develops and manufactures pharmaceutical products for the treatment of lung diseases. Its products are used for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. The company is located in London, the United Kingdom. | Directeur/Membre du Conseil | 01/05/2008 | 01/05/2008 |
AGENUS INC. | Corporate Officer/Principal | 01/08/2006 | 01/08/2006 |
University of Pennsylvania | Corporate Officer/Principal | - | 01/01/1997 |
Breath Therapeutics GmbH
![]() Breath Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Breath Therapeutics GmbH is a clinical stage biopharmaceutical company, which engages in the development of inhaled therapeutics for respiratory diseases. It offers drug device platform, which consists of liposomal drug-aerosol formulations and cutting-edge inhalation technology. The company was founded by Jens Stegemann, Gerhard Boerner, Oliver Denk, and Anne Burger in 2016 and is headquartered in Munchen, Germany. | Directeur/Membre du Conseil | 28/11/2017 | - |
CORBUS PHARMACEUTICALS HOLDINGS, INC. | Directeur/Membre du Conseil | 01/06/2014 | - |
Independent Dir/Board Member | 01/06/2014 | - | |
Novartis Pharmaceuticals Corp.
![]() Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Directeur Technique/Scientifique/R&D | - | - |
░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - |
Formation de Renu Gupta
University of Zambia | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 9 |
Zambie | 2 |
Royaume-Uni | 2 |
Opérationnelle
Director/Board Member | 4 |
Chief Tech/Sci/R&D Officer | 3 |
Corporate Officer/Principal | 3 |
Sectorielle
Health Technology | 8 |
Consumer Services | 4 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 3 |
---|---|
AGENUS INC. | Health Technology |
INSMED INCORPORATED | Health Technology |
CORBUS PHARMACEUTICALS HOLDINGS, INC. | Health Technology |
Entreprise privées | 5 |
---|---|
Transave, Inc.
![]() Transave, Inc. Pharmaceuticals: MajorHealth Technology Transave, Inc. is a biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. They are committed to significantly improving the quality of life and healthcare of patients suffering from these life-threatening diseases. Its operating principles are centered on teamwork, openness, mutual respect, diversity of opinion, trust, accountability and innovative science. They are developing products based on Transave's proprietary liposomal technology designed specifically for lung delivery. Its focus is on reformulating off-patent, established drugs into unique liposomal technology - based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases. Transave's proprietary liposomal technology allows for the sustained release of a drug in the lung's microenvironment. By remaining in the lungs for a prolonged period and potentially minimizing systemic exposure, Transave's liposomal technology offers the potential for changing the product profile, improving delivery of the compound to the lung and enhancing the therapeutic index of established pharmaceuticals. | Health Technology |
Novartis Pharmaceuticals Corp.
![]() Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Insmed Ltd.
![]() Insmed Ltd. Pharmaceuticals: MajorHealth Technology Insmed Ltd. develops and manufactures pharmaceutical products for the treatment of lung diseases. Its products are used for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. The company is located in London, the United Kingdom. | Health Technology |
Aim At Melanoma Foundation | |
Breath Therapeutics GmbH
![]() Breath Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Breath Therapeutics GmbH is a clinical stage biopharmaceutical company, which engages in the development of inhaled therapeutics for respiratory diseases. It offers drug device platform, which consists of liposomal drug-aerosol formulations and cutting-edge inhalation technology. The company was founded by Jens Stegemann, Gerhard Boerner, Oliver Denk, and Anne Burger in 2016 and is headquartered in Munchen, Germany. | Health Technology |
- Bourse
- Insiders
- Renu Gupta
- Expérience